Brilinta regulatory update

Germany's Federal Joint Committee (G-BA) issued a final benefit assessment for cardiovascular drug Brilique ticagrelor from AstraZeneca. G-BA said Brilique provides

Read the full 216 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE